June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen calls ... Read more

July 14, 2017August 29, 2017

FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too

News, Ulcerative colitis

U.S. regulators are considering extending their approval of Pfizer’s rheumatoid arthritis therapy Xeljanz to ulcerative colitis as well. That possibility surfaced when the Food and Drug Administration accepted Pfizer’s supplemental New Drug Application for Xeljanz ... Read more